secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKWELL MEDICAL, INC. (RMTI)
CIK:        0001041024
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001104659-24-002065
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 8.01, 2.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rockwell Medical extends loan maturity to 2029, provides preliminary Q4 net sales $21.3M-$22.3M
--------------------------------------------------------------------------------

- Amended loan with Innovatus: $8.0M principal, interest-only 30-36 months, maturity extended from Mar 2025 to Jan 2029.
- Issued warrant to Innovatus for 191,096 shares at $1.83 per share, exercisable through Jan 2029.
- Preliminary Q4 2023 net sales $21.3M-$22.3M (10-16% YoY growth); gross profit $1.6M-$2.6M; adj. EBITDA ($0.9M)-$0.1M.
- Full-year 2023 net sales projected $82.8M-$83.8M (14-15% growth); gross profit $7.4M-$8.4M; adj. EBITDA ($5.5M)-($4.5M).
- Cash and equivalents $11.0M at Dec 31, 2023, down slightly from $11.7M at Sep 30, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/0001104659-24-002065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1041024/000110465924002065/tm242195d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-002065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer